Literature DB >> 18687469

Oxidative DNA damage in bone marrow cells of patients with low-risk myelodysplastic syndrome.

Bozena Novotna1, Yana Bagryantseva, Magda Siskova, Radana Neuwirtova.   

Abstract

Bone marrow aspirates of 19 patients with low-risk myelodysplastic syndromes (MDS) and 14 control subjects were collected in order to assess the level of oxidative DNA damage. Glycophorin A positive and negative cells separated by miniMACS magnetic cell sorting were subjected to single cell gel electrophoresis (comet assay) combined with enzymes of base excision repair (endonuclease III and formamido-pyrimidine-glycosylase) that specifically recognize oxidized nucleotides. Compared to controls, MDS patients exhibited a significant increase of oxidative damage to DNA which could contribute to genomic instability and disease progression.

Entities:  

Mesh：

Year:  2008        PMID： 18687469     DOI： 10.1016/j.leukres.2008.07.005

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  17 in total

1.  A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.

Authors:  D Sanford; C C Hsia
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

Review 2.  Iron overload in myelodysplastic syndromes (MDS).

Authors:  Norbert Gattermann
Journal:  Int J Hematol       Date:  2017-11-25       Impact factor: 2.490

3.  Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine.

Authors:  Alena Moudra; Sona Hubackova; Veronika Machalova; Marketa Vancurova; Jiri Bartek; Milan Reinis; Zdenek Hodny; Anna Jonasova
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

Review 4.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Eliezer Rachmilewitz; Amit Verma; Yelena Ginzburg
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

5.  Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome.

Authors:  Yang Jo Chung; Carine Robert; Sheryl M Gough; Feyruz V Rassool; Peter D Aplan
Journal:  Leuk Res       Date:  2013-08-16       Impact factor: 3.156

6.  Mice heterozygous for CREB binding protein are hypersensitive to γ-radiation and invariably develop myelodysplastic/myeloproliferative neoplasm.

Authors:  Stephanie N Zimmer; Madeleine E Lemieux; Bijal P Karia; Claudia Day; Ting Zhou; Qing Zhou; Andrew L Kung; Uthra Suresh; Yidong Chen; Marsha C Kinney; Alexander J R Bishop; Vivienne I Rebel
Journal:  Exp Hematol       Date:  2011-12-20       Impact factor: 3.084

Review 7.  Oxidative stress, redox regulation and diseases of cellular differentiation.

Authors:  Zhi-Wei Ye; Jie Zhang; Danyelle M Townsend; Kenneth D Tew
Journal:  Biochim Biophys Acta       Date:  2014-11-15

8.  Oxidative stress levels are correlated with P15 and P16 gene promoter methylation in myelodysplastic syndrome patients.

Authors:  Ana Cristina Gonçalves; Emília Cortesão; Barbara Oliveiros; Vera Alves; Ana Isabel Espadana; Luís Rito; Emília Magalhães; Sónia Pereira; Amélia Pereira; José Manuel Nascimento Costa; Luisa Mota-Vieira; Ana Bela Sarmento-Ribeiro
Journal:  Clin Exp Med       Date:  2015-05-17       Impact factor: 3.984

9.  A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.

Authors:  Guillermo Garcia-Manero; Hanna J Khoury; Elias Jabbour; Jeffrey Lancet; Shannon L Winski; LouAnn Cable; Selena Rush; Lara Maloney; Grant Hogeland; Mieke Ptaszynski; Monica Cabrero Calvo; Zach Bohannan; Alan List; Hagop Kantarjian; Rami Komrokji
Journal:  Clin Cancer Res       Date:  2014-12-05       Impact factor: 12.531

Review 10.  Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA?

Authors:  Ting Zhou; Paul Hasty; Christi A Walter; Alexander J R Bishop; Linda M Scott; Vivienne I Rebel
Journal:  Exp Hematol       Date:  2013-04-30       Impact factor: 3.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.